Back to Top

RET

0 comments

Submitted by Annemieke DeMaggio on Tue, 09/08/2020 - 10:59

Accelerated FDA approval for pralsetinib in RET-fusion positive NSCLC

Approval based on the NSCLC cohorts included in the ARROW phase 1/2 study. Data from thyroid cancer cohorts has been filed; PDUFA in February 2021